AbbVie Inc (ABBV)vsGyre Therapeutics Inc. (GYRE)
ABBV
AbbVie Inc
$211.32
+3.64%
HEALTHCARE · Cap: $360.63B
GYRE
Gyre Therapeutics Inc.
$7.68
+4.49%
HEALTHCARE · Cap: $696.73M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 52358% more annual revenue ($61.16B vs $116.59M). ABBV leads profitability with a 6.9% profit margin vs 4.3%. ABBV trades at a lower P/E of 100.0x. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
GYRE
Hold39
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Intrinsic value data unavailable for GYRE.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Revenue surging 33.4% year-over-year
Earnings expanding 166.2% YoY
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
Smaller company, higher risk/reward
4.3% margin — thin
Operating margin of 0.3%
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : GYRE
The strongest argument for GYRE centers on Revenue Growth, EPS Growth. Revenue growth of 33.4% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : GYRE
The primary concerns for GYRE are Market Cap, Profit Margin, Operating Margin. A P/E of 381.5x leaves little room for execution misses. Thin 4.3% margins leave little buffer for downturns.
Key Dynamics to Monitor
ABBV profiles as a value stock while GYRE is a hypergrowth play — different risk/reward profiles.
GYRE carries more volatility with a beta of 6.40 — expect wider price swings.
GYRE is growing revenue faster at 33.4% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 39/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Gyre Therapeutics Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Gyre Therapeutics Inc. is a cutting-edge biopharmaceutical company dedicated to developing innovative therapies for rare and complex diseases. By utilizing a proprietary platform, Gyre accelerates the discovery and commercialization of precision treatments aimed at addressing significant unmet medical needs. The company's strong focus on scientific excellence and patient-centered outcomes, coupled with its advancing pipeline in gene therapy and precision medicine, positions Gyre for substantial growth within the competitive biopharmaceutical landscape. Through strategic partnerships and a commitment to research, Gyre is poised to make a meaningful impact on the lives of patients facing challenging health conditions.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?